FMS - Dialysis stocks decline again as Novo Nordisk hits 52-week high
2023-10-12 13:24:12 ET
More on Baxter, DaVita, etc.
- Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
- Outset Medical Faces Regulatory Delays Amid Heavy Cash Burn (Rating Downgrade)
- DaVita: Continued Economic Hurdles, Market Expectations May Be Correct
- Lilly stock hits new 52-week high amid Ozempic study news (update)
- Dialysis stocks tumble on Ozempic kidney failure study news (update)
For further details see:
Dialysis stocks decline again as Novo Nordisk hits 52-week high